Research notes

The report states a BUY rating on Apollo Hospitals.

The report maintains a BUY rating with a Sep-27 target price of INR 5,300, citing strong Q2FY27 execution with revenue up 17%, EBITDA up 50%, and earnings up 67%, driven by premiumization and raised FY27 P&A volume growth guidance to 30%.

The report says IndiaMart delivered a moderate quarter with ARPU-led growth offsetting declining paying subscribers, maintaining ADD with a DCF-based TP of INR 1,900.

The report says Acutaas Chemicals beat Q2 estimates on EBITDA/APAT but maintains SELL due to high near-term valuations, with TP of INR 2,427.

The report says JK Cement delivered strong volume growth and EBITDA growth in Q2FY27, maintaining BUY with unchanged TP of INR 6,130.

The report says MDL posted a disappointing quarter with declining revenue and EBITDA due to weak order book execution, but maintains a long-term constructive ADD rating with reduced multiple and TP of INR 2,300.

The report says Tata Capital's Q2FY27 earnings beat estimates on lower credit costs and AUM growth despite NIM compression, maintaining ADD with a revised TP of INR 365.

The report says SBI Life beat estimates on APE/VNB growth and margin expansion from product mix shift, maintaining a high-conviction BUY with revised TP of INR2,320.

The report says L&T beat revenue and APAT estimates with record order book and robust order inflows, maintaining BUY with a revised SOTP target of INR 4,680.

The note says the ETF's weekly chart shows a sustainable bounce from support near Rs 15.56 with a bullish higher-tops-and-bottoms pattern and positive RSI bias, suggesting a buying range of Rs 16.73-16.36 with a stop-loss of Rs 15.47.

The note says the ETF's weekly chart shows a sustainable bounce from support near Rs 157 with a bullish higher-tops-and-bottoms pattern and positive RSI bias, suggesting a buying range of Rs 166.50-162.90 with a stop-loss of Rs 154.05.

The report notes the company received NCLT approval for a composite scheme merging three wholly owned subsidiaries into the parent, effective April 1, 2024.

The report states Ather Energy turned net profitable in Q2FY27 with revenue up 63% YoY to Rs 1,464.24 crore and approved fresh capex of Rs 122 crore.

The report notes Q2FY27 consolidated revenue jumped 35% YoY to a record Rs 1,547 crore, driven by a 129% YoY surge in BEV revenue.

The report states Q2FY27 net profit rose 10.73% YoY to Rs 181.52 crore with AUM up 16.1% YoY and improved cost-to-income ratio.

The report notes Q2FY27 net profit surged 41.42% YoY to Rs 2,310 crore with NII up 21.76% and a sharp drop in NPA provisions.

The report states revenue grew 12.6% YoY to Rs 892.4 crore with net profit up 53% YoY, and the stock trades at 18.5x FY29E EPS.

The report notes revenue grew 31% YoY to Rs 560.4 crore and net profit rose 83% YoY to Rs 24.2 crore.

The report states Mankind Pharma's revenue grew 17.3% YoY to Rs 4,338 crore, beating estimates, with net profit up 39% YoY and the stock trading at 26.5x FY29E EPS.

The report notes revenue grew 17% YoY to Rs 120.5 crore and EBITDA rose 49% with margin expanding to 23.7%.

The report states revenue rose sharply to Rs 825 crore and net profit to Rs 858 crore, aided by a one-time gain of Rs 868 crore.

The report notes Brigade Hotel Ventures' net profit doubled to Rs 22 crore with revenue up 10% YoY and EBITDA margin improving to 34.85%.

The report states Dalmia Bharat posted a net loss of Rs 205 crore in Q2 FY27 versus a profit a year ago, with EBITDA falling 29.2% and margin contracting.

The report notes Tata Consumer's revenue grew 14.0% YoY to Rs 5,661 crore with EBITDA up 16.6% YoY and PAT up 17.7% YoY.

The report states ITC Hotels' consolidated revenue rose 25.6% YoY to Rs 1,054 crore and EBITDA grew 37.3% YoY with margin at 32.0%.